Bay City Capital
Bay City Capital LLC (Bay City Capital), established in 1997 , specializes in investments in the life sciences industry.
Business Model:
Revenue: $8.4M
Employees: 2-10
Rankings
Industries / Tags:
Detailed Bay City Capital Information
Geographic Data
Address: 750 Battery St
City: San Francisco
State: CA
Zip: 94111
Country: US
Financial Info
Stage:
Raised Last:
$0
Raised Total:$2M
Social
Twitter
Linkedin
Crunchbase
Metrics
7,558,103Website Global Rank
502Website Monthly Traffic
Twitter Followers
Description
Bay City Capital LLC (Bay City Capital) was established in 1997 for the purpose of managing investment funds in the life sciences industry. Since that date, they have managed six venture funds representing $1.5 billion in capital invested in over 70 companies. Five of these funds are general life sciences funds, and one is a nutrition and agribusiness sector fund.
Contact Phone:
+14156763830
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 10/2013 | PharmAkea | Series A | 10M |
| 12/2014 | Interleukin Genetics | Post-IPO Equity | 5M |
| 6/2011 | Aviir | Venture Round | 3M |
| 4/2005 | Phenomix | Series B | 20M |
| 3/2009 | VIA Pharmaceuticals | Debt Financing | 10M |
| 7/2018 | Gossamer Bio | Series B | 0 |
| 10/2017 | Gritstone Bio | Venture Round | - |
| 4/2012 | Thermogenesis | Post-IPO Equity | - |
| 10/2013 | Cydan | Venture Round | 10M |
| 12/1997 | Chemdex | Seed Round | - |
| 3/2000 | AquaBounty Technologies | Venture Round | - |
| 11/2002 | Pathway Diagnostics | Venture Round | - |
| 5/2013 | Interleukin Genetics | Post-IPO Equity | 12M |
| 7/2005 | BrainCells | Series A | 0 |
| 4/2000 | Ingenuity Systems | Venture Round | - |
| 3/2008 | IDEV Technologies | Series C | 14.4M |
| 3/2009 | Accriva Diagnostics | Venture Round | - |
| 2/2006 | NeoRX Corporation (Poniard Pharmaceuticals) | Post-IPO Equity | 65M |
| 12/2004 | CymaBay Therapeutics | Series B | 44M |
| 3/1999 | VNUS Medical Technologies | Venture Round | - |
| 8/2004 | Avera Pharmaceutical | Series C | 0 |
| 12/2002 | Bioren | Seed Round | - |
| 8/2007 | Presidio Pharmaceuticals | Series B | 26M |
| 8/2000 | Epocrates | Series B | 35M |
| 8/2002 | Epocrates | Series C | - |
| 1/2005 | Calypso Medical | Series C | 6.8M |
| 5/2007 | Vivaldi Biosciences | Series A | 2M |
| 10/2014 | SynGen | Venture Round | - |
| 4/2012 | SynGen | Series A | 5M |
| 1/2018 | Oculis | Series B | 20.5M |
| 1/2002 | BioSeek | Venture Round | - |
| 5/2021 | Oculis | Series C | 0 |
| 2/2002 | Syntonix Pharmaceuticals | Series B | 35.8M |
| 1/2008 | Aragon Surgical | Series B | 25M |
| 11/2000 | Panomics | Seed Round | - |
| 3/2002 | Reliant Pharmaceuticals | Series C | 160M |
| 1/2010 | Merus | Series B | 0 |
| 11/2009 | CymaBay Therapeutics | Series E | 0 |
| 9/2007 | Aciex Therapeutics | Series A | - |
| 1/1999 | Lexicon Pharmaceuticals | Post-IPO Equity | 0 |
| 2/2011 | Conatus Pharmaceuticals | Series B | 0 |
| 10/2013 | Galecto | Series B | 6.3M |
| 8/2003 | CymaBay Therapeutics | Series A | 27M |
| 8/2000 | Intarcia Therapeutics | Venture Round | - |
| 1/2004 | PTC Therapeutics | Series E | 35M |
| 5/2017 | Xeris Pharmaceuticals | Series C | 0 |
| 9/2000 | Senomyx | Series B | 10M |
| 10/2016 | Bridge Medicines | Venture Round | - |
| 6/2017 | Twist Bioscience | Venture Round | 27M |
| 7/2016 | Vtesse | Series A | 17M |
| 10/2010 | IDEV Technologies | Series D | 46M |
| 9/2010 | EnteroMedics | Post-IPO Equity | 6.3M |
| 7/2004 | EnteroMedics | Series A | - |
| 4/2009 | Sunesis Pharmaceuticals | Post-IPO Equity | 0 |
| 6/2013 | Dermira | Series B | 35M |
| 6/2009 | Hyperion Therapeutics | Series C | 60M |
| 4/2014 | Madrigal Pharmaceuticals | Post-IPO Equity | - |
| 3/2007 | Phenomix | Series C | 55M |
| 3/2010 | Ion Torrent | Series C | 37.1M |
| 11/1997 | Maxia Pharmaceuticals | Venture Round | - |
| 11/2000 | Helios Health | Venture Round | 0 |
| 9/2001 | PTC Therapeutics | Series D | 0 |
| 11/2005 | PTC Therapeutics | Private Equity Round | 26.6M |
| 1/2014 | Fabric Genomics (formerly Omicia) | Series A | 6.8M |
| 1/2006 | MAP Pharmaceuticals | Series C | 25.2M |
| 9/2004 | MAP Pharmaceuticals | Series B | 30M |
| 10/2009 | Aviir | Venture Round | 1M |
| 6/2003 | Phenomix | Series A | 11.6M |
| 1/1999 | LJL Biosystems | Post-IPO Equity | - |
| 8/2005 | Protez Pharmaceuticals | Series B | 15M |
| 12/2008 | Aviir | Venture Round | 7.8M |
| 6/2013 | Aviir | Series B | 10M |
| 1/2010 | Aviir | Venture Round | 4.2M |
| 1/1998 | Pharminex | Venture Round | - |
| 9/2007 | Aviir | Series B | 11.3M |
| 10/2005 | Radiant Medical | Venture Round | 36M |
| 9/2006 | NuPathe | Series A | 15M |
| 10/2003 | Reliant Pharmaceuticals | Series D | 115M |
| 1/2016 | Imara | Seed Round | 800k |
| 11/2012 | Ascendancy | Venture Round | - |
| 5/2017 | Iterum Therapeutics | Series B | 65M |
| 11/2009 | Calypso Medical | Series E | 50M |
| 12/2003 | Avera Pharmaceutical | Series B | 8M |
| 7/2012 | GenturaDx | Series C | 21M |
| 3/2007 | MAP Pharmaceuticals | Series D | 50M |
| 12/2011 | Aviir | Venture Round | 10M |
| 3/2008 | Aviir | Venture Round | 1.5M |
| 10/2020 | Sembiosys Genetics | Venture Round | - |
| 12/2006 | NBI Development | Seed Round | 5.5M |
| 9/2013 | Civitas Therapeutics | Series B | 0 |
| 2/2012 | Altheos | Series A | 12.5M |
| 6/2004 | PTC Therapeutics | Series E | 0 |
| 4/2010 | Altheos | Series A | 20M |
| 7/2017 | VYNE Therapeutics | Series C | 50.5M |
| 3/2013 | Nabsys | Series D | 35M |
| 7/2004 | Phenomix | Series A | 2M |
| 3/2019 | Imara | Series B | 0 |
| 1/2018 | KBP Biosciences | Series A | 0 |
| 2/2007 | PTC Therapeutics | Series F | 10M |
| 10/2011 | Dermira | Series A | 42M |
| 4/2016 | Imara | Series A | 31M |
| 7/2013 | TRIA Beauty | Private Equity Round | 0 |
| 1/2011 | NextWave Pharmaceuticals | Series C | 45M |
| 10/2002 | Oculex Pharmaceuticals | Series B | 50M |
| 10/2013 | Merus | Series B | 42.2M |
| 4/2015 | Merus | Series C | 79.1M |
| 7/2011 | Nevro | Series B | 58M |
| 12/2006 | Nevro | Seed Round | 5.5M |
| 9/2008 | Nevro | Series A | 21.8M |
| 10/2009 | Epizyme | Series B | 32M |
| 8/2014 | Civitas Therapeutics | Series C | 0 |
| 10/2002 | Pharmion | Venture Round | 40M |
| 8/2014 | Dermira | Series C | 51M |
| 3/2002 | Phenomix | Series A | 12M |
| 1/2015 | Vtesse | Series A | 25M |
| 3/2013 | Nevro | Series C | 0 |
| 2/2009 | Cadence Pharmaceuticals | Post-IPO Equity | 86.6M |
| 3/2020 | Xilio Therapeutics | Series B | 100.5M |
| 5/2007 | Conatus Pharmaceuticals | Series A | 22M |
| 7/2017 | Kezar Life Sciences | Series B | 0 |
| 11/2020 | Bridge Medicines | Equity | 10M |
| 11/2018 | NextCure | Series B | 93M |
| 2/2008 | Cadence Pharmaceuticals | Post-IPO Equity | - |
| 2/2013 | Aviir | Series B | 10M |
| 8/2000 | Syrrx | Series A | 5.1M |
| 6/2002 | Itamar Medical | Venture Round | - |
| 4/2002 | Avera Pharmaceutical | Series A | 20M |
| 7/2008 | NuPathe | Series B | 30M |
| 1/2009 | Vivaldi Biosciences | Series A | 23M |
| 3/2008 | BrainCells | Series B | 30M |
| 5/2021 | Oculis | Series C | 0 |
| 11/2020 | Bridge Medicines | Venture Round | 0 |
| 10/2020 | Sembiosys Genetics | Venture Round | - |
| 3/2020 | Xilio Therapeutics | Series B | 0 |
| 3/2019 | Imara | Series B | 0 |
| 11/2018 | NextCure | Series B | 0 |
| 7/2018 | Gossamer Bio | Series B | 0 |
| 1/2018 | KBP Biosciences | Series A | 0 |
| 1/2018 | Oculis | Series B | 0 |
| 10/2017 | Gritstone Bio | Venture Round | - |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
